Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced stage ovarian cancer of epithelial origin. small cell lung carcinoma. carcinoma of the head and neck. carcinoma of the testis. paediatric cerebral tumours. soft tissue sarcoma and neuroblastoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced stage ovarian cancer of epithelial origin. small cell lung carcinoma. carcinoma of the head and neck. carcinoma of the testis. paediatric cerebral tumours. soft tissue sarcoma and neuroblastoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - for the treatment of advanced stage ovarian cancer of epithelial origin. small cell lung carcinoma. carcinoma of the head and neck. carcinoma of the testis. paediatric cerebral tumours. soft tissue sarcoma and neuroblastoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; citric acid; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of:,? breast cancer,? gastric cancer,? ovarian cancer,? small cell lung cancer,? lymphoma (non-hodgkin?s lymphoma),? advanced/metastatic soft tissue sarcoma,? superficial bladder cancer (tis; ta).,in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of:,? breast cancer,? gastric cancer,? ovarian cancer,? small cell lung cancer,? lymphoma (non-hodgkin?s lymphoma),? advanced/metastatic soft tissue sarcoma,? superficial bladder cancer (tis; ta).,in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases and is indicated for the treatment of:,? breast cancer,? gastric cancer,? ovarian cancer,? small cell lung cancer,? lymphoma (non-hodgkin?s lymphoma),? advanced/metastatic soft tissue sarcoma,? superficial bladder cancer (tis; ta).,in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: arginine; sodium hydroxide; dilute hydrochloric acid; hydroxypropylbetadex - voriconazole is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp. and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.